Amaurosis fugax: Difference between revisions

m (Ostermayer moved page Amaurosis Fugax to Amaurosis fugax)
 
(20 intermediate revisions by 6 users not shown)
Line 1: Line 1:
==Background==
==Background==
*Transient painless visual loss caused by either circulatory, ocular or a neurologic condition. Vision loss can last a few seconds to minutes.<ref>Fisher CM et al. "'Transient monocular blindness' versus 'amaurosis fugax'". Neurology. December 1989. 39 (12): 1622–4. doi:10.1212/wnl.39.12.1622. PMID 2685658</ref>
[[File:Schematic diagram of the human eye en.png|thumb|Eye anatomy.]]
*Transient painless [[visual loss]] caused by either circulatory, ocular or a neurologic condition. Vision loss can last a few seconds to minutes.<ref>Fisher CM et al. "'Transient monocular blindness' versus 'amaurosis fugax'". Neurology. December 1989. 39 (12): 1622–4. doi:10.1212/wnl.39.12.1622. PMID 2685658</ref>
*Fugax is greek for "fleeing"
*Fugax is greek for "fleeing"
*Greatest suspicion in assessing these patients should be to evaluation for acute stroke and embolic phenomenon as that will carry the greatest mortality<ref>Benavente O et al. "Prognosis after transient monocular blindness associated with carotid-artery stenosis". N. Engl. J. Med. 345 (15): 1084–90. doi:10.1056/NEJMoa002994. PMID 11596587 [http://www.nejm.org/doi/pdf/10.1056/NEJMoa002994 Full text]</ref>
*Greatest suspicion in assessing these patients should be to evaluation for acute [[stroke]] and embolic phenomenon as that will carry the greatest mortality<ref>Benavente O et al. "Prognosis after transient monocular blindness associated with carotid-artery stenosis". N. Engl. J. Med. 345 (15): 1084–90. doi:10.1056/NEJMoa002994. PMID 11596587 [http://www.nejm.org/doi/pdf/10.1056/NEJMoa002994 Full text]</ref>
 
==Clinical Features==
==Clinical Features==
*Patients report complete blackening of vision.
*Patients report complete blackening of vision.
==Differential Diagnosis==
==Differential Diagnosis==
''Causes are divided into '''embolic''', '''hemodynamic''', '''ocular''', '''neurologic''', and '''idiopathic''' <ref> "Current management of amaurosis fugax. The Amaurosis Fugax Study Group". Stroke 21 (2): 201–8. February 1990. doi:10.1161/01.STR.21.2.201. PMID 2406992 [http://stroke.ahajournals.org/content/21/2/201.full.pdf Full Text]</ref>
''Causes are divided into '''embolic''', '''hemodynamic''', '''ocular''', '''neurologic''', and '''idiopathic''' <ref> "Current management of amaurosis fugax. The Amaurosis Fugax Study Group". Stroke 21 (2): 201–8. February 1990. doi:10.1161/01.STR.21.2.201. PMID 2406992 [http://stroke.ahajournals.org/content/21/2/201.full.pdf Full Text]</ref>
Line 12: Line 15:
**[[Central Retinal Vein Occlusion (CRVO)]]
**[[Central Retinal Vein Occlusion (CRVO)]]
*Drug abuse-related intravascular emboli
*Drug abuse-related intravascular emboli
===Hemodynamic===
===Vascular/Hemodynamic===
*Carotid stenosis
*[[Carotid stenosis]]
*Arteritis ([[Temporal arteritis]], Takayasu's arteritis)
*Arteritis ([[Temporal arteritis]], [[Takayasu arteritis]])
*Hypoperfusion ([[CHF]], [[Hyperviscosity syndrome]], hyper coagulable state)<ref>Bacigalupi M et al. "Amaurosis Fugax-A Clinical Review". The Internet Journal of Allied Health Sciences and Practice. 2006 4 (2): 1–6.[http://ijahsp.nova.edu/articles/vol4num2/Bacigalupi.pdf Fulltext]</ref><ref>Mundall J, Quintero P, Von Kaulla KN, Harmon R, Austin J (March 1972). "Transient monocular blindness and increased platelet aggregability treated with aspirin. A case report". Neurology 22 (3): 280–5.</ref>
*Hypoperfusion ([[CHF]], [[Hyperviscosity syndrome]], hypercoagulable state)<ref>Bacigalupi M et al. "Amaurosis Fugax-A Clinical Review". The Internet Journal of Allied Health Sciences and Practice. 2006 4 (2): 1–6.[http://ijahsp.nova.edu/articles/vol4num2/Bacigalupi.pdf Fulltext]</ref><ref>Mundall J, Quintero P, Von Kaulla KN, Harmon R, Austin J (March 1972). "Transient monocular blindness and increased platelet aggregability treated with aspirin. A case report". Neurology 22 (3): 280–5.</ref>
 
===Ocular===
===Ocular===
*Ischemic optic neuropathy
*Ischemic optic neuropathy
Line 31: Line 35:
*[[Intracranial mass]]
*[[Intracranial mass]]
*[[Intracranial hemorrhage]]
*[[Intracranial hemorrhage]]
*[[Multiple sclerosis]]
*[[Multiple Sclerosis]]
*Psychogenic
*Psychogenic
===Idiopathic===
===Idiopathic===
*Diagnosis of exclusion
*Diagnosis of exclusion
==Workup==
 
{{Acute vision loss noninflamed DDX}}
 
==Evaluation==
''Workup will focus will vary significantly based on the differential and clinical presentation''
''Workup will focus will vary significantly based on the differential and clinical presentation''


In general it includes:
In general it includes:
*ECG
*[[ECG]]
*CT Brain non con and CTA head and neck
*[[CT brain]] non con and CTA head and neck
*Chest Xray
*[[CXR]]
*Basic Metabolic Panel
*Basic Metabolic Panel
*CBC (to assess for severe anemia or thrombocytosis)
*CBC (to assess for severe anemia or thrombocytosis)
*INR (if patient is anticogulated)
*INR (if patient is anticoagulated)
*MRI (if suspicion for [[CVA]], [[Multiple sclerosis]], or undifferentiated mass lesion)
*[[brain MRI|MRI]] (if suspicion for [[CVA]], [[Multiple Sclerosis]], or undifferentiated [[intracranial mass|mass lesion]])
*Ocular ultrasound (evaluate for retinal detachment or hemorrhage)  
*[[Ocular ultrasound]] (evaluate for [[retinal detachment]] or [[retinal hemorrhage|hemorrhage]])
*[[ESR/CRP]] (evaluate for [[Temporal Arteritis]]
 
==Management==
==Management==
''management also varies also based final diagnosis''
''Management also varies also based final diagnosis''
*Intrinsic ocular causes require ophtho evaluation and referral
*Intrinsic ocular causes require ophtho evaluation and referral
*Cardiologic cause requires medicine admission and cardiology consultation
*Cardiologic cause requires admission and cardiology consultation
*Neurologic causes require medicine admission and neurologic consultation  
*Neurologic causes require admission and neurologic consultation  
*Hematologic causes or vasculatisis related causes will require medicine evaluation and sub specialist consultation
*Hematologic causes or vasculitis related causes will require sub specialist consultation
 
==Disposition==
==Disposition==
*Close followup or admission depending on the final determined cause
*Close follow-up or admission depending on the final determined cause
==See Also==
==See Also==
[[Acute_Vision_Loss_(Noninflamed)]]
*[[Acute vision loss (noninflamed)]]
 
==External Links==
==External Links==


==Sources==
==References==
<references/>
<references/>
[[Category:Neurology]]
[[Category:Ophthalmology]]
[[Category:Vascular]]

Latest revision as of 17:38, 13 July 2025

Background

Eye anatomy.
  • Transient painless visual loss caused by either circulatory, ocular or a neurologic condition. Vision loss can last a few seconds to minutes.[1]
  • Fugax is greek for "fleeing"
  • Greatest suspicion in assessing these patients should be to evaluation for acute stroke and embolic phenomenon as that will carry the greatest mortality[2]

Clinical Features

  • Patients report complete blackening of vision.

Differential Diagnosis

Causes are divided into embolic, hemodynamic, ocular, neurologic, and idiopathic [3]

Embolic

Vascular/Hemodynamic

Ocular

Neurologic

Idiopathic

  • Diagnosis of exclusion

Acute Vision Loss (Noninflamed)

Emergent Diagnosis

Evaluation

Workup will focus will vary significantly based on the differential and clinical presentation

In general it includes:

Management

Management also varies also based final diagnosis

  • Intrinsic ocular causes require ophtho evaluation and referral
  • Cardiologic cause requires admission and cardiology consultation
  • Neurologic causes require admission and neurologic consultation
  • Hematologic causes or vasculitis related causes will require sub specialist consultation

Disposition

  • Close follow-up or admission depending on the final determined cause

See Also

External Links

References

  1. Fisher CM et al. "'Transient monocular blindness' versus 'amaurosis fugax'". Neurology. December 1989. 39 (12): 1622–4. doi:10.1212/wnl.39.12.1622. PMID 2685658
  2. Benavente O et al. "Prognosis after transient monocular blindness associated with carotid-artery stenosis". N. Engl. J. Med. 345 (15): 1084–90. doi:10.1056/NEJMoa002994. PMID 11596587 Full text
  3. "Current management of amaurosis fugax. The Amaurosis Fugax Study Group". Stroke 21 (2): 201–8. February 1990. doi:10.1161/01.STR.21.2.201. PMID 2406992 Full Text
  4. Bacigalupi M et al. "Amaurosis Fugax-A Clinical Review". The Internet Journal of Allied Health Sciences and Practice. 2006 4 (2): 1–6.Fulltext
  5. Mundall J, Quintero P, Von Kaulla KN, Harmon R, Austin J (March 1972). "Transient monocular blindness and increased platelet aggregability treated with aspirin. A case report". Neurology 22 (3): 280–5.
  6. Mattsson, P, Lundberg, PO. Characteristics and prevalence of transient visual disturbances indicative of migraine visual aura. Cephalalgia. Jun 1999;19(5):477.